Abstract: The present disclosure relates to methods for improving the safety profile of adoptive cell transfer therapies. In particular, the present disclosure relates to methods for improving the safety profile of CAR T-cell therapies. Disclosed is an anti-CD25 antibody-drug-conjugate for use in a method of treatment or prevention of CAR immune cell toxicity in an individual.

Abstract: Systems and methods are provided for drug development under a fully transparent development model. The model is configured to provide transparency to the patients, the researchers, clinicians, physicians, and any other registered users of the system who wish to contribute. According to various embodiments, the system and model enable drug development that leverage the combined wisdom and insight of the user population eliminating many of the drawbacks of conventional development approaches. In one embodiment, the system includes drug development engine configured to manage execution of parameters of a clinical trial, including collection of health and treatment information from a patient population. The development engine can publish collected execution data for review and analysis.

Abstract: Systems and methods are provided for drug development under a fully transparent development model. The model is configured to provide transparency to the patients, the researchers, clinicians, physicians, and any other registered users of the system who wish to contribute. According to various embodiments, the system and model enable drug development that leverage the combined wisdom and insight of the user population eliminating many of the drawbacks of conventional development approaches. In one embodiment, the system includes drug development engine configured to manage execution of parameters of a clinical trial, including collection of health and treatment information from a patient population. The development engine can publish collected execution data for review and analysis.

Abstract: According to another aspect, clinical trial execution can be improved based on a paradigm shift to a remote model. In various embodiments, the system manages and executes an asynchronous visit, that is a system based visit simulating doctor or clinician interaction for a respective clinical trial participant or a patient medical visit. According to various embodiments, the asynchronous visit enables patient or participant interaction with the system unbounded by time or place—this represents a leap forward in clinical trial execution, as both trained personnel availability and location restriction have significantly limited the ability to conduct trials. In some examples, these limitations have prevented qualified participants from engaging with a trial run. Thus the system avoids a variety of known problem with conventional trial execution, and for example, situations where a trial with a small qualifying population cannot afford to lose even one qualified patient.

Abstract: Systems and methods are provided for drug development under a fully transparent development model. The model is configured to provide transparency to the patients, the researchers, clinicians, physicians, and any other registered users of the system who wish to contribute. According to various embodiments, the system and model enable drug development that leverage the combined wisdom and insight of the user population eliminating many of the drawbacks of conventional development approaches. In one embodiment, the system includes drug development engine configured to manage execution of parameters of a clinical trial, including collection of health and treatment information from a patient population. The development engine can publish collected execution data for review and analysis.

Abstract: Systems and methods are provided for drug development under a fully transparent development model. The model is configured to provide transparency to the patients, the researchers, clinicians, physicians, and any other registered users of the system who wish to contribute. According to various embodiments, the system and model enable drug development that leverage the combined wisdom and insight of the user population eliminating many of the drawbacks of conventional development approaches. In one embodiment, the system includes drug development engine configured to manage execution of parameters of a clinical trial, including collection of health and treatment information from a patient population. The development engine can publish collected execution data for review and analysis.

Abstract: Systems and methods are provided for drug development under a fully transparent development model. The model is configured to provide transparency to the patients, the researchers, clinicians, physicians, and any other registered users of the system who wish to contribute. According to various embodiments, the system and model enable drug development that leverage the combined wisdom and insight of the user population eliminating many of the drawbacks of conventional development approaches. In one embodiment, the system includes drug development engine configured to manage execution of parameters of a clinical trial, including collection of health and treatment information from a patient population. The development engine can publish collected execution data for review and analysis.

Abstract: The invention relates to the use of an accelerated lymphocyte homing agent, e.g. a 2-amino-1,3-propanediol derivative, in reducing delayed graft function in a recipient of organ or tissue transplant.

Abstract: The invention relates to the use of an accelerated lymphocyte homing agent, e.g. a 2-amino-1,3-propanediol derivative, in reducing delayed graft function in a recipient of organ or tissue transplant.